Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Saeed, Kamal (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08008342
ABSTRACT:
Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.
REFERENCES:
patent: 2954380 (1960-09-01), Shapiro et al.
patent: 3218328 (1965-11-01), Shapiro et al.
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4179501 (1979-12-01), Szmuszkovicz
patent: 4598087 (1986-07-01), Horwell
patent: 4656182 (1987-04-01), Horwell
patent: 4663343 (1987-05-01), Horwell et al.
patent: 4855316 (1989-08-01), Horwell et al.
patent: 4880800 (1989-11-01), Wallis et al.
patent: 4906655 (1990-03-01), Horwell et al.
patent: 5019588 (1991-05-01), Horwell et al.
patent: 5051428 (1991-09-01), Horwell et al.
patent: 5059620 (1991-10-01), Stout et al.
patent: 5492825 (1996-02-01), Jan et al.
patent: 5506257 (1996-04-01), MacLeod et al.
patent: 5637583 (1997-06-01), MacLeod et al.
patent: 5670335 (1997-09-01), Jan et al.
patent: 5728535 (1998-03-01), Lester et al.
patent: 5734021 (1998-03-01), Lester et al.
patent: 5750537 (1998-05-01), Nomura et al.
patent: 5817698 (1998-10-01), Brown et al.
patent: 5885984 (1999-03-01), MacLeod et al.
patent: 6174879 (2001-01-01), MacLeod et al.
patent: 6180632 (2001-01-01), Myers et al.
patent: 6210809 (2001-04-01), Okutomi et al.
patent: 6214810 (2001-04-01), Fermini et al.
patent: 6451819 (2002-09-01), Alanine et al.
patent: 6521619 (2003-02-01), Link et al.
patent: 6649603 (2003-11-01), Sum
patent: 6979685 (2005-12-01), Beatch et al.
patent: 7053087 (2006-05-01), Beatch et al.
patent: 7057053 (2006-06-01), Beatch et al.
patent: 7259184 (2007-08-01), Beatch et al.
patent: 7345086 (2008-03-01), Beatch et al.
patent: 7345087 (2008-03-01), Beatch et al.
patent: 7507545 (2009-03-01), Fedida et al.
patent: 2005/0038256 (2005-02-01), Barrett et al.
patent: 2005/0070552 (2005-03-01), Fedida et al.
patent: 2006/0252753 (2006-11-01), Beatch et al.
patent: 2007/0099983 (2007-05-01), Barrett et al.
patent: 2007/0197632 (2007-08-01), Beatch et al.
patent: 2007/0254945 (2007-11-01), Jung et al.
patent: 1234808 (1988-04-01), None
patent: 1235122 (1988-04-01), None
patent: 2004575 (1990-06-01), None
patent: 2058502 (1993-06-01), None
patent: 2172513 (1995-03-01), None
patent: 2244209 (1997-07-01), None
patent: 2008391 (1997-12-01), None
patent: 2289055 (1999-01-01), None
patent: 2268590 (2000-10-01), None
patent: 2132841 (2001-03-01), None
patent: 2 259 260 (1974-06-01), None
patent: 2 658 401 (1978-07-01), None
patent: 3 517 901 (1985-12-01), None
patent: 222533 (1987-05-01), None
patent: 147085 (1990-03-01), None
patent: 147085 (1990-03-01), None
patent: 372466 (1990-06-01), None
patent: 372466 (1990-06-01), None
patent: 380063 (1990-08-01), None
patent: 380063 (1990-08-01), None
patent: 552386 (1993-07-01), None
patent: 720605 (1996-07-01), None
patent: 215963 (1995-02-01), None
patent: 02-270864 (1990-11-01), None
patent: WO 93/19056 (1993-09-01), None
patent: WO 94/07843 (1994-04-01), None
patent: WO 94/14435 (1994-07-01), None
patent: WO 95/08544 (1995-03-01), None
patent: WO 95/28155 (1995-10-01), None
patent: WO 96/18615 (1996-06-01), None
patent: WO 96/23894 (1996-08-01), None
patent: WO 97/32857 (1997-09-01), None
patent: WO 97/49680 (1997-12-01), None
patent: WO 99/02159 (1999-01-01), None
patent: WO 99/03468 (1999-01-01), None
patent: WO 99/11252 (1999-03-01), None
patent: WO 99/16431 (1999-04-01), None
patent: WO 99/50205 (1999-10-01), None
patent: WO 99/50225 (1999-10-01), None
patent: WO 00/47547 (2000-08-01), None
patent: WO 00/51981 (2000-09-01), None
patent: WO 01/96335 (2001-12-01), None
patent: WO 03/105756 (2003-12-01), None
patent: WO 2004/008103 (2004-01-01), None
patent: WO 2004/098525 (2004-11-01), None
patent: WO 2004/099137 (2004-11-01), None
Adcock et al., “RSD931, a novel anti-tussive agent acting on airway sensory nerves”,Br J Pharm138(3):407-416, 2003.
Altria et al., “Capillary Electrophoresis as a Routine Analytical Tool in Pharmaceutical Analysis”,LCGC19(9): 972-985, Sep. 2001.
Amin et al., “RPR 101821, a New Potent Cholesterol-lowering Agent: Inhibition of Squalene Synthase and 7-Dehydrocholesterol Reductase”,Naunyn-Schmiedeberg's Arch Pharmacol353:233-240, 1996.
Alzheimer's Disease Information Page [online], [retrieved on Oct. 3, 2006]. Retrieved from the Internet, URL: <http://www.ninds.nih.gov/disorders/alzheimersdisease/alzheimersdisease.htm>.
Bain et al., “Better Antiarrhythmics? Development of Antiarrhythmic Drugs Selective for Ischaemia-Dependent Arrhythmias”,Drug Development Research42:198-210, 1997.
Barrett and Walker, “Glibenclamide Possesses Transient, Ischaemia Selective Class III Antiarrhythmic Actions But Does Not Prevent Ischaemic Arrhythmias”,BPS Proceedings116P, 1996.
Barrett et al., “A Model of Myocardial Ischemia for the Simultaneous Assessment of Electrophysiological Changes and Arrhythmias in Intact Rabbits”,J Pharmacol Toxicol Methods37(1):27-36, 1997.
Barrett et al., “Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats”,Eur J Pharm398:365-374, 2000.
Barrett et al., “Atypical Dose Response Curves for Antiarrhythmic Drugs”,BPS Proceedings115P, 1996.
Barrett, “Ischemia Selective Electrophysiological and Antiarrhythmic Actions of RSD1019 in Ischemic Cardiac Tissue”,J Mol Cell Cardiol29:197, 1997.
Barrett et al., “RSD1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits”,Br J Pharm131(3):405-414, 2000.
Beatch et al., “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodelled Atria”,Pharmacologist44(2) (Supp I), A15: XIVthWorld Congress of Pharmacology: Meeting Abstracts, 2002. Abstract No. 22.11.
Beatch et al., “Effect of a Novel Anti-tussive Compound CP1 Against Citric Acid Induced Cough in Guinea-Pigs”,Proc West Pharmacol Soc44:252, 2001.
Beatch et al., “Electrophysiological Profile of RSD1235, A New Drug for Conversion of Atrial Fibrillation”, Abstract of U.S. Appl. No. 10/674,684, filed Sep. 29, 2003, now U.S. Patent No. 7,101,877 issued Sep. 5, 2006.
Beatch et al., “RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation”, Abstract submission ESC Congress Aug. 30-Sep. 3, 2003, in Vienna, Austria.
Beatch et al., “RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man”, 12thInternational Congress on Cardiovascular Pharmacotherapy, May 7-10, 2003, Barcelona, Spain.
Beatch et al., “Ventricular Fibrillation, an Uncontrolled Arrhythmia Seeking New Targets”,Drug Develop Res55:45-52, 2002.
Beatch, “Antihistamine-induced Ventricular Arrhythmias”,BPS Proceedings120P, 1996.
Beatch et al., “Characterization of a Non-Human Primate Model of Drug-Induced Torsades De Pointes”,Proc West Pharmacol Soc40:13-16, 1997.
Beatch et al., “RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodelled Atria”,PACE24(Part II):698. Abstract 702, May 10, 2002.
Bian et al., “Effects of Kappa-opioid receptor stimulation in the heart and the involvement of protein kinase C”,Brit J Pharm124:600-606, 1998.
Billman, “RSD-1235”,Curr Opin Investigational Drugs4(3):352-354, 2003.
Boiadjiev and Lightner, “pH-Sensitive Exciton Chirality Chromophore. Solvatochromic Effects on Circular Dichroism Spectra”,Tetrahedron: Asymmetry7(10):2825-2832, 1996.
Bowen et al., “Characterization of the Enantiomers of cis-N-[2-(3,4- Dichlorophenyl)Ethyl]-N-Methyl-2-(1-Pyrrolidinyl)Cyclohexylamine (BD737 and BD738): Novel Compounds with High Affinity, Selectivity and Biological Efficacy at Sigma Receptors”,J Pharmacol Exp Ther262(1):32-4
Beatch Gregory N.
Plouvier Bertrand M. C.
Sheng Tao
Walker Michael J. A.
Wall Richard A.
Bianchi Kristin
Cardiome Pharma Corp.
Saeed Kamal
Seed IP Law Group PLLC
LandOfFree
Ion channel modulating compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ion channel modulating compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ion channel modulating compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2770804